{"nctId":"NCT00195715","briefTitle":"Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease","startDateStruct":{"date":"2004-09"},"conditions":["Crohn's Disease"],"count":777,"armGroups":[],"interventions":[{"name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must have successfully completed either the M02-404 (NCT00077779) or M04-691 (NCT00105300) protocol to be eligible for this study\n* Diagnosis of Crohn's disease\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Diagnosis of ulcerative colitis\n* Women cannot be pregnant or breastfeeding\n* Previous history of listeria infection or untreated tuberculosis\n* Previous history of cancer other than successfully treated skin cancer or carcinoma-in-situ of the cervix","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Percentage of Subjects Achieving Clinical Remission","description":"Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \\< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Clinical Remission","description":"Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \\< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Achieving Clinical Remission","description":"Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \\< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Clinical Remission","description":"Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \\< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Clinical Response 100 (CR-100)","description":"A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Clinical Response 70 (CR-70)","description":"A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Steroid-free Clinical Remission","description":"Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of \\<150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Steroid-free CR-100","description":"Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Fistula Remission","description":"Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Infection","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Serious Infection","description":"Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Malignancy","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Lymphoma","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Nonmelanoma Skin Cancer","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Injection Site Reaction-related Adverse Event","description":"An injection site reaction is any adverse event corresponding to a preferred term beginning with \"injection site\" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Congestive Heart Failure","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Demyelinating Disease","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Hepatic-related Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Allergic Reaction-related Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Lupus-like Syndrome","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Hematologic-related Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Fatal Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":296,"n":777},"commonTop":["Crohn's disease","Nasopharyngitis","Arthralgia","Abdominal pain","Upper respiratory tract infection"]}}}